ECONOMIC NEWS
December 24, 1996
ISRAELI SATELLITE "AMOS" WILL SUPPLY 30 PERCENT OF HUNGARIAN ANTENNA
COMPANY'S SERVICES
("Ha'aretz" 20.12)
An agreement has been signed to increase to 30 percent the level of the
services to be supplied to the Hungarian Antenna Company for radio and
television broadcasts, through the Israeli communications satellite
"Amos." The company is a partner in the Hungarian Magyars satellite
project, together with the Israeli Aircraft Industries, who will build an
additional satellite to provide services for countries in Eastern Europe,
and mutual technical backup and marketing for the existing "Amos"
satellite.
ERNEST YOUNG CORP. TO INCLUDE ISRAEL IN SCIENTIFIC REVIEWS
("Ma'ariv" 22.12)
Starting next year, the international Ernest Young Corporation will
start including Israel in its worldwide reviews of information systems.
The representative consultant to the company in Israel, Dror Foukard, says
two reviews will feature Israel. He said they will enable, for the first
time, simultaneous comparisons between the status of a scientific systems
manager in Israel and elsewhere in the world, and comparisons with
countries with which Israel competes or attempts to increase its marketing
penetration. The Ernest Young representation in Israel is Kost, Lev-Ari
and Ford, which has 25 experts in various fields, including industrial and
managerial engineers, systems analysts, accountants, and graduates of
business administration.
FIRST ISRAELI TRADE FAIR IN JORDAN
("Yediot Aharonot" 22.12)
Israel's first trade fair in Jordan will open on January 6, and will
last three days. The Jordanian government succeeded in overcoming the
local opposition to the fair being held, arguing it affected the private
sector, and was not under official government auspices. The fair will be
held in the fair grounds outside Amman, under the sponsorship of the
Israeli-Jordanian Chamber of Commerce, and will include pavillions of
Israeli companies maintaining trade with Jordan.
"TEVA" RECEIVES FINAL APPROVAL TO MARKET COPEXONE IN U.S.
("Ha'aretz" 24.12)
The Israeli Teva Pharmaceutical Co. has been informed by the U.S. Food
and Drug Administration that it has been finally approved to market its
drug Copexone in the U.S. The medication is an original product of Teva,
for treating multiple sclerosis. It had been anticipated that the approval
would arrive before the end of 1996, and the drug can now go on sale
throughout the U.S. The approval will help Teva receive similar approvals
from other countries, including Israel. It cannot market the medication in
Europe until such approval is received, starting with Britain and then the
rest of the continent. Its sales in the U.S. are expected to begin in
February, but not later than April. The annual treatment by the drug will
cost patients between $7,000 and $10,000. Teva's shares on Wall Street
went up by 0.6 percent following the news.